ReviewInternational journal of molecular sciences2016
MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 7 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.Prostate cancer and prostatic diseases · 2022Pooled it
- Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis.Bioscience reports · 2022Pooled it
- Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients.Journal of translational medicine · 2021Pooled it
- Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis.Disease markers · 2020Pooled it
- Circulating microRNA biomarkers for lung cancer detection in Western populations.Cancer medicine · 2018Pooled it
- Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis.Oncotarget · 2017Pooled it
- The accuracy of microRNA-210 in diagnosing lung cancer: a systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.PloS one · 2019Trial
- Article
- miR-3613-5p promotes lung cancer progression by targeting and regulating XPO6.Discover oncology · 2025Article
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- A machine learning-based screening model for the early detection of prostate cancer developed using serum microRNA data from a mixed cohort of 8,741 participants.Discover oncology · 2025Article
- lncRNA SNHG4 enhanced gastric cancer progression by modulating miR-409-3p/CREB1 axis.Oncology research · 2025Article
- MicroRNAs in breast cancer-new frontiers in diagnosis, targeted therapy, and prognosis assessment.Frontiers in oncology · 2025Review
- MiRNA Dysregulation in Brain Injury: AnCurrent neuropharmacology · 2025Article
- Recent progress in microRNA research for prostate cancer.Discover oncology · 2024Review
- MiR-134-5p inhibits the malignant phenotypes of osteosarcoma via ITGB1/MMP2/PI3K/Akt pathway.Cell death discovery · 2024Article
- miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023Review
- Integrated co-expression analysis of regulatory elements (miRNA, lncRNA, and TFs) in bovine monocytes induced by Str. uberis.Scientific reports · 2023Article
- Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer.Functional & integrative genomics · 2022Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) includes several phenotypes, from indolent to highly aggressive cancer. Actual diagnostic and prognostic tools have several limitations, and there is a need for new biomarkers to stratify patients and assign them optimal therapies by taking into account potential genetic and epigenetic differences. MicroRNAs (miRNAs) are small sequences of non-coding RNA regulating specific genes involved in the onset and development of PC. Stable miRNAs have been found in biofluids, such as serum and plasma; thus, the measurement of PC-associated miRNAs is emerging as a non-invasive tool for PC detection and monitoring. In this study, we conduct an in-depth literature review focusing on miRNAs that may contribute to the diagnosis and prognosis of PC. The role of miRNAs as a potential theranostic tool in PC is discussed. Using a meta-analysis approach, we found a group of 29 miRNAs with diagnostic properties and a group of seven miRNAs with prognostic properties, which were found already expressed in both biofluids and PC tissues. We tested the two miRNA groups on The Cancer Genome Atlas dataset of PC tissue samples with a machine-learning approach. Our results suggest that these 29 miRNAs should be considered as potential panel of biomarkers for the diagnosis of PC, both as in vivo non-invasive test and ex vivo confirmation test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.